Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion p... Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1 | -12.7388535032 | 7.85 | 8.0272 | 6.266 | 590106 | 6.98961957 | CS |
4 | -1.02 | -12.9606099111 | 7.87 | 9.18 | 6.266 | 465909 | 7.64225587 | CS |
12 | -0.15 | -2.14285714286 | 7 | 11.2 | 6.266 | 512239 | 8.18352599 | CS |
26 | -1.87 | -21.4449541284 | 8.72 | 11.2 | 5.91 | 495664 | 8.02278623 | CS |
52 | 2.59 | 60.7981220657 | 4.26 | 13.68 | 2.18 | 406357 | 8.25608389 | CS |
156 | -5.29 | -43.5749588138 | 12.14 | 13.685 | 1.53 | 254841 | 6.34133668 | CS |
260 | -5.15 | -42.9166666667 | 12 | 25.87 | 1.53 | 202167 | 7.20570526 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.